Seminars in Nuclear Medicine
Volume 39, Issue 6 , Pages 396-407 , November 2009

Prostate Cancer: Role of SPECT and PET in Imaging Bone Metastases

  • Mohsen Beheshti, MD, FEBNM, FASNC

      Affiliations

    • Department of Nuclear Medicine and Endocrinology, PET-CT Center Linz, St Vincent's Hospital, Linz, Austria
    • Corresponding Author InformationAddress reprint requests to Mohsen Beheshti, MD, FEBNM, FASNC, Department of Nuclear Medicine and Endocrinology, PET-CT Center Linz, St Vincent's Hospital, A-4020 Linz, Austria
    • ,
  • Werner Langsteger, MD, FACE

      Affiliations

    • Department of Nuclear Medicine and Endocrinology, PET-CT Center Linz, St Vincent's Hospital, Linz, Austria
    • ,
  • Ignac Fogelman, BSc, MD, FRCP

      Affiliations

    • Division of Imaging, King's College, London, United Kingdom

References 

  1. Coleman RE. Skeletal complications of malignancy. Cancer. 1997;80(suppl 8):1588–1594
  2. Berenson JR, Rajdev L, Broder M. Pathophysiology of bone metastases. Cancer Biol Ther. 2006;5:1078–1081
  3. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2007. CA Cancer J Clin. 2007;57:43–66
  4. Blum D. Prostate Cancer: Can We Reduce Mortality While Preserving the Quality of Life? (vol 1). Washington, DC: US Department of Health and Human Services; 1995;
  5. Davidson P, Gabbay J. Should mass screening for prostate cancer be introduced at the national level?. WHO Regional Office for Europe's Health Evidence Network Report (HEN); 2004;
  6. Jemal A, Murray T, Ward E, et al. Cancer statistics, 2005. CA Cancer J Clin. 2005;55:10–30
  7. D'Amico AV, Whittington R, Schnall M, et al. The impact of the inclusion of endorectal coil magnetic resonance imaging in a multivariate analysis to predict clinically unsuspected extraprostatic cancer. Cancer. 1995;75:2368–2372
  8. Rosenthal DI. Radiologic diagnosis of bone metastases. Cancer. 1997;80(suppl 8):1595–1607
  9. Krasnow AZ, Hellman RS, Timins ME, et al. Diagnostic bone scanning in oncology. Semin Nucl Med. 1997;27:107–141
  10. Han LJ, Au-Yong TK, Tong WC, et al. Comparison of bone single-photon emission tomography and planar imaging in the detection of vertebral metastases in patients with back pain. Eur J Nucl Med. 1998;25:635–638
  11. Kosuda S, Kaji T, Yokoyama H, et al. Does bone SPECT actually have lower sensitivity for detecting vertebral metastasis than MRI?. J Nucl Med. 1996;37:975–978
  12. Savelli G, Chiti A, Grasselli G, et al. The role of bone SPET study in diagnosis of single vertebral metastases. Anticancer Res. 2000;20:1115–1120
  13. Choueiri MB, Tu SM, Yu-Lee LY, et al. The central role of osteoblasts in the metastasis of prostate cancer. Cancer Metastasis Rev. 2006;25:601–609
  14. Lehr JE, Pienta KJ. Preferential adhesion of prostate cancer cells to a human bone marrow endothelial cell line. J Natl Cancer Inst. 1998;90:118–123
  15. Scott LJ, Clarke NW, George NJ, et al. Interactions of human prostatic epithelial cells with bone marrow endothelium: Binding and invasion. Br J Cancer. 2001;84:1417–1423
  16. Goya M, Ishii G, Miyamoto S, et al. Prostate-specific antigen induces apoptosis of osteoclast precursors: Potential role in osteoblastic bone metastases of prostate cancer. Prostate. 2006;66:1573–1584
  17. Dotan ZA. Bone imaging in prostate cancer. Nat Clin Pract Urol. 2008;5:434–444
  18. Savelli G, Maffioli L, Maccauro M, et al. Bone scintigraphy and the added value of SPECT (single photon emission tomography) in detecting skeletal lesions. Q J Nucl Med. 2001;45:27–37
  19. de Jong IJ, Pruim J, Elsinga PH, et al. Preoperative staging of pelvic lymph nodes in prostate cancer by 11C-choline PET. J Nucl Med. 2003;44:331–335
  20. Jacobson A, Fogelman I, Rosenthall L. Bone scanning in metastatic disease. In:  Collier BD editors. Skeletal Nuclear Medicine. St Louis, MO: Mosby; 1996;p. 87–123
  21. O'Mara RE. Skeletal scanning in neoplastic disease. Cancer. 1976;37(suppl 1):480–486
  22. Roland J, van den Weyngaert D, Krug B, et al. Metastases seen on SPECT imaging despite a normal planar bone scan. Clin Nucl Med. 1995;20:1052–1054
  23. Horiuchi-Suzuki K, Saji H, Ohta H, et al. Reply. Eur J Nucl Med Mol Imaging. Oct. 23, 2004;
  24. Horiuchi-Suzuki K, Konno A, Ueda M, et al. Skeletal affinity of Tc(V)-DMS is bone cell mediated and pH dependent. Eur J Nucl Med Mol Imaging. 2004;31:388–398
  25. Sabbatini P, Larson SM, Kremer A, et al. Prognostic significance of extent of disease in bone in patients with androgen-independent prostate cancer. J Clin Oncol. 1999;17:948–957
  26. Noguchi M, Kikuchi H, Ishibashi M, et al. Percentage of the positive area of bone metastasis is an independent predictor of disease death in advanced prostate cancer. Br J Cancer. 2003;88:195–201
  27. Rigaud J, Tiguert R, Le NL, et al. Prognostic value of bone scan in patients with metastatic prostate cancer treated initially with androgen deprivation therapy. J Urol. 2002;168:1423–1426
  28. Lund F, Smith PH, Suciu S. Do bone scans predict prognosis in prostatic cancer? (A report of the EORTC protocol 30762). Br J Urol. 1984;56:58–63
  29. D'Amico AV, Whittington R, Malkowicz SB, et al. Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. JAMA. 1998;280:969–974
  30. Kattan MW, Eastham JA, Stapleton AM, et al. A preoperative nomogram for disease recurrence following radical prostatectomy for prostate cancer. J Natl Cancer Inst. 1998;90:766–771
  31. Oesterling JE, Martin SK, Bergstralh EJ, et al. The use of prostate-specific antigen in staging patients with newly diagnosed prostate cancer. JAMA. 1993;269:57–60
  32. Sanz G, Rioja J, Zudaire JJ, et al. PET and prostate cancer. World J Urol. 2004;22:351–352
  33. Chybowski FM, Keller JJ, Bergstralh EJ, et al. Predicting radionuclide bone scan findings in patients with newly diagnosed, untreated prostate cancer: Prostate specific antigen is superior to all other clinical parameters. J Urol. 1991;145:313–318
  34. Lee CT, Oesterling JE. Using prostate-specific antigen to eliminate the staging radionuclide bone scan. Urol Clin North Am. 1997;24:389–394
  35. Cher ML, Bianco FJ, Lam JS, et al. Limited role of radionuclide bone scintigraphy in patients with prostate specific antigen elevations after radical prostatectomy. J Urol. 1998;160:1387–1391
  36. Kane CJ, Amling CL, Johnstone PA, et al. Limited value of bone scintigraphy and computed tomography in assessing biochemical failure after radical prostatectomy. Urology. 2003;61:607–611
  37. Dotan ZA, Bianco FJ, Rabbani F, et al. Pattern of prostate-specific antigen (PSA) failure dictates the probability of a positive bone scan in patients with an increasing PSA after radical prostatectomy. J Clin Oncol. 2005;23:1962–1968
  38. Cook GJ, Fogelman I. The role of nuclear medicine in monitoring treatment in skeletal malignancy. Semin Nucl Med. 2001;31:206–211
  39. Koizumi M, Matsumoto S, Takahashi S, et al. Bone metabolic markers in the evaluation of bone scan flare phenomenon in bone metastases of breast cancer. Clin Nucl Med. 1999;24:15–20
  40. Imbriaco M, Larson SM, Yeung HW, et al. A new parameter for measuring metastatic bone involvement by prostate cancer: The Bone Scan Index. Clin Cancer Res. 1998;4:1765–1772
  41. Yahara J, Noguchi M, Noda S. Quantitative evaluation of bone metastases in patients with advanced prostate cancer during systemic treatment. BJU Int. 2003;92:379–383discussion 383-374
  42. Even-Sapir E, Martin RH, Barnes DC, et al. Role of SPECT in differentiating malignant from benign lesions in the lower thoracic and lumbar vertebrae. Radiology. 1993;187:193–198
  43. Gates GF. SPECT bone scanning of the spine. Semin Nucl Med. 1998;28:78–94
  44. Jacobson AF, Fogelman I. Bone scanning in clinical oncology: Does it have a future?. Eur J Nucl Med. 1998;25:1219–1223
  45. Uematsu T, Yuen S, Yukisawa S, et al. Comparison of FDG PET and SPECT for detection of bone metastases in breast cancer. Am J Roentgenol. 2005;184:1266–1273
  46. Even-Sapir E, Metser U, Mishani E, et al. The detection of bone metastases in patients with high-risk prostate cancer: 99mTc-MDP planar bone scintigraphy, single- and multi-field-of-view SPECT, 18F-fluoride PET, and 18F-fluoride PET/CT. J Nucl Med. 2006;47:287–297
  47. Song X, Segars WP, Du Y, et al. Fast modelling of the collimator-detector response in Monte Carlo simulation of SPECT imaging using the angular response function. Phys Med Biol. 2005;50:1791–1804
  48. Bander NH, Milowsky MI, Nanus DM, et al. Phase I trial of 177lutetium-labeled J591, a monoclonal antibody to prostate-specific membrane antigen, in patients with androgen-independent prostate cancer. J Clin Oncol. 2005;23:4591–4601
  49. Galsky MD, Eisenberger M, Moore-Cooper S, et al. Phase I trial of the prostate-specific membrane antigen-directed immunoconjugate MLN2704 in patients with progressive metastatic castration-resistant prostate cancer. J Clin Oncol. 2008;26:2147–2154
  50. Milowsky MI, Nanus DM, Kostakoglu L, et al. Phase I trial of yttrium-90-labeled anti-prostate-specific membrane antigen monoclonal antibody J591 for androgen-independent prostate cancer. J Clin Oncol. 2004;22:2522–2531
  51. Morris MJ, Divgi CR, Pandit-Taskar N, et al. Pilot trial of unlabeled and indium-111-labeled anti-prostate-specific membrane antigen antibody J591 for castrate metastatic prostate cancer. Clin Cancer Res. 2005;11:7454–7461
  52. Troyer SS, Beckett VE, Wright WD. Location of prostate-specific membrane antigen in the LNCaP prostate carcinoma cell line. Prostate. 1997;30:232–242
  53. Chang SS, Reuter VE, Heston WD, et al. Five different anti-prostate-specific membrane antigen (PSMA) antibodies confirm PSMA expression in tumor-associated neovasculature. Cancer Res. 1999;59:3192–3198
  54. Bander N, Nanus D, Bremer S. Phase I clinical trial targeting a monoclonal antibody (mAb) to the extracellular domain of prostate specific membrane antigen (PSMAext) in hormone-independent patients. J Urol. 2000;163(suppl 4):160–167
  55. Seo Y, Franc BL, Hawkins RA, et al. Progress in SPECT/CT imaging of prostate cancer. Technol Cancer Res Treat. 2006;5:329–336
  56. Silver DA, Pellicer I, Fair WR, et al. Prostate-specific membrane antigen expression in normal and malignant human tissues. Clin Cancer Res. 1997;3:81–85
  57. Sweat SD, Pacelli A, Murphy GP, et al. Prostate-specific membrane antigen expression is greatest in prostate adenocarcinoma and lymph node metastases. Urology. 1998;52:637–640
  58. Wright GL, Grob BM, Haley C, et al. Upregulation of prostate-specific membrane antigen after androgen-deprivation therapy. Urology. 1996;48:326–334
  59. Babaian RJ, Sayer J, Podoloff DA, et al. Radioimmunoscintigraphy of pelvic lymph nodes with 111indium-labeled monoclonal antibody CYT-356. J Urol. 1994;152:1952–1955
  60. Haseman MK, Reed NL, Rosenthal SA. Monoclonal antibody imaging of occult prostate cancer in patients with elevated prostate-specific antigen (Positron emission tomography and biopsy correlation). Clin Nucl Med. 1996;21:704–713
  61. Hinkle GH, Burgers JK, Neal CE, et al. Multicenter radioimmunoscintigraphic evaluation of patients with prostate carcinoma using indium-111 capromab pendetide. Cancer. 1998;83:739–747
  62. Polascik TJ, Manyak MJ, Haseman MK, et al. Comparison of clinical staging algorithms and 111indium-capromab pendetide immunoscintigraphy in the prediction of lymph node involvement in high risk prostate carcinoma patients. Cancer. 1999;85:1586–1592
  63. Texter JH, Neal CE. The role of monoclonal antibody in the management of prostate adenocarcinoma. J Urol. 1998;160:2393–2395
  64. Apolo AB, Pandit-Taskar N, Morris MJ. Novel tracers and their development for the imaging of metastatic prostate cancer. J Nucl Med. 2008;49:2031–2041
  65. Cook GJ, Fogelman I. The role of positron emission tomography in the management of bone metastases. Cancer. 2000;88(suppl 12):2927–2933
  66. Valk PE, Pounds TR, Tesar RD, et al. Cost-effectiveness of PET imaging in clinical oncology. Nucl Med Biol. 1996;23:737–743
  67. Gambhir SS, Shepherd JE, Shah BD, et al. Analytical decision model for the cost-effective management of solitary pulmonary nodules. J Clin Oncol. 1998;16:2113–2125
  68. Bombardieri E, Aktolun C, Baum RP, et al. FDG-PET: Procedure guidelines for tumour imaging. Eur J Nucl Med Mol Imaging. 2003;30:BP115–BP124
  69. Warburg O. On the origin of cancer cells. Science. 1956;123:309–314
  70. Minn H, Clavo AC, Wahl RL. Influence of hypoxia on tracer accumulation in squamous-cell carcinoma: In vitro evaluation for PET imaging. Nucl Med Biol. 1996;23:941–946
  71. Singh G, Lakkis CL, Laucirica R, et al. Regulation of prostate cancer cell division by glucose. J Cell Physiol. 1999;180:431–438
  72. Rossi F, Grzeskowiak M, Della BV, et al. Novo synthesis of diacylglycerol from glucose (A new pathway of signal transduction in human neutrophils stimulated during phagocytosis of beta-glucan particles). J Biol Chem. 1991;266:8034–8038
  73. Effert PJ, Bares R, Handt S, et al. Metabolic imaging of untreated prostate cancer by positron emission tomography with 18fluorine-labeled deoxyglucose. J Urol. 1996;155:994–998
  74. Shreve PD, Grossman HB, Gross MD, et al. Metastatic prostate cancer: Initial findings of PET with 2-deoxy-2-[F-18]fluoro-d-glucose. Radiology. 1996;199:751–756
  75. Yeh SD, Imbriaco M, Larson SM, et al. Detection of bony metastases of androgen-independent prostate cancer by PET-FDG. Nucl Med Biol. 1996;23:693–697
  76. Cook GJ, Houston S, Rubens R, et al. Detection of bone metastases in breast cancer by 18FDG PET: Differing metabolic activity in osteoblastic and osteolytic lesions. J Clin Oncol. 1998;16:3375–3379
  77. Agus DB, Golde DW, Sgouros G, et al. Positron emission tomography of a human prostate cancer xenograft: Association of changes in deoxyglucose accumulation with other measures of outcome following androgen withdrawal. Cancer Res. 1998;58:3009–3014
  78. Seltzer MA, Barbaric Z, Belldegrun A, et al. Comparison of helical computerized tomography, positron emission tomography and monoclonal antibody scans for evaluation of lymph node metastases in patients with prostate specific antigen relapse after treatment for localized prostate cancer. J Urol. 1999;162:1322–1328
  79. Oyama N, Akino H, Kanamaru H, et al. 11C-acetate PET imaging of prostate cancer. J Nucl Med. 2002;43:181–186
  80. Steinborn MM, Heuck AF, Tiling R, et al. Whole-body bone marrow MRI in patients with metastatic disease to the skeletal system. J Comput Assist Tomogr. 1999;23:123–129
  81. Hetzel M, Hetzel J, Arslandemir C, et al. Reliability of symptoms to determine use of bone scans to identify bone metastases in lung cancer: Prospective study. BMJ. 2004;328:1051–1052
  82. Schirrmeister H, Arslandemir C, Glatting G, et al. Omission of bone scanning according to staging guidelines leads to futile therapy in non-small cell lung cancer. Eur J Nucl Med Mol Imaging. 2004;31:964–968
  83. Langsteger W, Heinisch M, Fogelman I. The role of fluorodeoxyglucose, 18F-dihydroxyphenylalanine, 18F-choline, and 18F-fluoride in bone imaging with emphasis on prostate and breast. Semin Nucl Med. 2006;36:73–92
  84. Morris MJ, Akhurst T, Osman I, et al. Fluorinated deoxyglucose positron emission tomography imaging in progressive metastatic prostate cancer. Urology. 2002;59:913–918
  85. Costello LC, Franklin RB. Citrate metabolism of normal and malignant prostate epithelial cells. Urology. 1997;50:3–12
  86. Yoshimoto M, Waki A, Yonekura Y, et al. Characterization of acetate metabolism in tumor cells in relation to cell proliferation: Acetate metabolism in tumor cells. Nucl Med Biol. 2001;28:117–122
  87. Shreve PD, Gross MD. Imaging of the pancreas and related diseases with PET carbon-11-acetate. J Nucl Med. 1997;38:1305–1310
  88. Shreve P, Chiao PC, Humes HD, et al. Carbon-11-acetate PET imaging in renal disease. J Nucl Med. 1995;36:1595–1601
  89. Oyama N, Miller TR, Dehdashti F, et al. 11C-acetate PET imaging of prostate cancer: Detection of recurrent disease at PSA relapse. J Nucl Med. 2003;44:549–555
  90. Kotzerke J, Volkmer BG, Neumaier B, et al. Carbon-11 acetate positron emission tomography can detect local recurrence of prostate cancer. Eur J Nucl Med Mol Imaging. 2002;29:1380–1384
  91. Albrecht S, Buchegger F, Soloviev D, et al. (11)C-acetate PET in the early evaluation of prostate cancer recurrence. Eur J Nucl Med Mol Imaging. 2007;34:185–196
  92. Ponde DE, Dence CS, Oyama N, et al. 18F-fluoroacetate: A potential acetate analog for prostate tumor imaging—In vivo evaluation of 18F-fluoroacetate versus 11C-acetate. J Nucl Med. 2007;48:420–428
  93. Matthies A, Ezziddin S, Ulrich EM, et al. Imaging of prostate cancer metastases with 18F-fluoroacetate using PET/CT. Eur J Nucl Med Mol Imaging. 2004;31:797
  94. Cimitan M, Bortolus R, Morassut S, et al. [(18)F]fluorocholine PET/CT imaging for the detection of recurrent prostate cancer at PSA relapse: Experience in 100 consecutive patients. Eur J Nucl Med Mol Imaging. 2006;33:1387–1398
  95. Kwee SA, Wei H, Sesterhenn I, et al. Localization of primary prostate cancer with dual-phase 18F-fluorocholine PET. J Nucl Med. 2006;47:262–269
  96. Reske SN, Blumstein NM, Neumaier B, et al. Imaging prostate cancer with 11C-choline PET/CT. J Nucl Med. 2006;47:1249–1254
  97. Hara T, Kosaka N, Shinoura N, et al. Imaging of brain tumor with [methyl-11C]choline. J Nucl Med. 1997;38:842–847
  98. Hara T, Kosaka N, Kishi HP. Imaging of prostate cancer using carbon-11-choline. J Nucl Med. 1998;39:990–995
  99. Hara T, Inagaki K, Kosaka N, et al. Sensitive detection of mediastinal lymph node metastasis of lung cancer with 11C-choline PET. J Nucl Med. 2000;41:1507–1513
  100. Kobori O, Kirihara Y, Kosaka N, et al. Positron emission tomography of esophageal carcinoma using (11)C-choline and (18)F-fluorodeoxyglucose: A novel method of preoperative lymph node staging. Cancer. 1999;86:1638–1648
  101. Breeuwsma AJ, Pruim J, Jongen MM, et al. In vivo uptake of [11C]choline does not correlate with cell proliferation in human prostate cancer. Eur J Nucl Med Mol Imaging. 2005;32:668–673
  102. Zheng QH, Gardner TA, Raikwar S, et al. [11C]choline as a PET biomarker for assessment of prostate cancer tumor models. Bioorg Med Chem. 2004;12:2887–2893
  103. Hara T, Kosaka N, Kishi H. Development of (18)F-fluoroethylcholine for cancer imaging with PET: Synthesis, biochemistry, and prostate cancer imaging. J Nucl Med. 2002;43:187–199
  104. DeGrado TR, Coleman RE, Wang S, et al. Synthesis and evaluation of 18F-labeled choline as an oncologic tracer for positron emission tomography: Initial findings in prostate cancer. Cancer Res. 2001;61:110–117
  105. DeGrado TR, Baldwin SW, Wang S, et al. Synthesis and evaluation of (18)F-labeled choline analogs as oncologic PET tracers. J Nucl Med. 2001;42:1805–1814
  106. DeGrado TR, Reiman RE, Price DT, et al. Pharmacokinetics and radiation dosimetry of 18F-fluorocholine. J Nucl Med. 2002;43:92–96
  107. Langsteger W, Beheshti M, Nader M, et al. Evaluation of lymph node and bone metastases with fluor choline (FCH) PET—CT in the follow up of prostate cancer patients. Eur J Nucl Med Mol Imaging. 2006;33(suppl 2):208–209
  108. Langsteger W, Beheshti M, Loidl W, et al. Fluor choline (FCH) PET—CT in preoperative staging of prostate cancer. Eur J Nucl Med Mol Imaging. 2006;33(suppl 2):207–208
  109. Beheshti M, Vali R, Langsteger W. [18F]fluorocholine PET/CT in the assessment of bone metastases in prostate cancer. Eur J Nucl Med Mol Imaging. 2007;34:1316–1317author reply 1318-1319
  110. Schmid DT, John H, Zweifel R, et al. Fluorocholine PET/CT in patients with prostate cancer: Initial experience. Radiology. 2005;235:623–628
  111. Husarik DB, Miralbell R, Dubs M, et al. Evaluation of [(18)F]-choline PET/CT for staging and restaging of prostate cancer. Eur J Nucl Med Mol Imaging. 2008;35:253–263
  112. Beheshti M, Vali R, Waldenberger P, et al. The use of F-18 choline PET in the assessment of bone metastases in prostate cancer: Correlation with morphological changes on CT. Mol Imaging Biol. 2009;[Epub ahead of print]
  113. Langsteger W, Beheshti M, Pöcher S, et al. Fluor choline (FCH) PET—CT in preoperative staging and follow up of prostate cancer. Mol Imaging Biol. 2006;8:69
  114. Beheshti M, Haim S, Nader M, et al. Assessment of bone metastases in patients with prostate cancer by dual—phase F–18 fluor choline PET/CT. Eur J Nucl Med Mol Imaging. 2006;33(Suppl 2):208
  115. Beheshti M, Vali R, Langsteger W. [18F]fluorocholine PET/CT in the assessment of bone metastases in prostate cancer. Eur J Nucl Med Mol Imaging. 2007;34:1316–1317
  116. Blau M, Nagler W, Bender MA. Fluorine-18: A new isotope for bone scanning. J Nucl Med. 1962;3:332–334
  117. Schirrmeister H, Guhlmann A, Elsner K, et al. Sensitivity in detecting osseous lesions depends on anatomic localization: Planar bone scintigraphy versus 18F PET. J Nucl Med. 1999;40:1623–1629
  118. Fogelman I, Cook G, Israel O, et al. Positron emission tomography and bone metastases. Semin Nucl Med. 2005;35:135–142
  119. Petren-Mallmin M, Andreasson I, Ljunggren O, et al. Skeletal metastases from breast cancer: Uptake of 18F-fluoride measured with positron emission tomography in correlation with CT. Skeletal Radiol. 1998;27:72–76
  120. Hawkins RA, Choi Y, Huang SC, et al. Evaluation of the skeletal kinetics of fluorine-18-fluoride ion with PET. J Nucl Med. 1992;33:633–642
  121. Schirrmeister H, Guhlmann A, Kotzerke J, et al. Early detection and accurate description of extent of metastatic bone disease in breast cancer with fluoride ion and positron emission tomography. J Clin Oncol. 1999;17:2381–2389
  122. Beheshti M, Vali R, Waldenberger P, et al. Detection of bone metastases in patients with prostate cancer by 18F fluorocholine and 18F fluoride PET-CT: A comparative study. Eur J Nucl Med Mol Imaging. 2008;35:1766–1774
  123. Alavi A, Kung JW, Zhuang H. Implications of PET based molecular imaging on the current and future practice of medicine. Semin Nucl Med. 2004;34:56–69
  124. Ishiwata K, Ido T, Vaalburg W. Increased amounts of D-enantiomer dependent on alkaline concentration in the synthesis of L-[methyl-11C]methionine. Int J Rad Appl Instrum [A]. 1988;39:311–314
  125. Miyazawa H, Arai T, Iio M, et al. Imaging of non-small-cell lung carcinoma with carbon-11-methionine: Relationship between radioactivity uptake and flow-cytometric parameters. J Nucl Med. 1993;34:1886–1891
  126. Nunez R, Macapinlac HA, Yeung HW, et al. Combined 18F-FDG and 11C-methionine PET scans in patients with newly progressive metastatic prostate cancer. J Nucl Med. 2002;43:46–55
  127. Toth G, Lengyel Z, Balkay L, et al. Detection of prostate cancer with 11C-methionine positron emission tomography. J Urol. 2005;173:66–69discussion 69
  128. Bonasera TA, O'Neil JP, Xu M, et al. Preclinical evaluation of fluorine-18-labeled androgen receptor ligands in baboons. J Nucl Med. 1996;37:1009–1015
  129. Scher HI, Sawyers CL. Biology of progressive, castration-resistant prostate cancer: Directed therapies targeting the androgen-receptor signaling axis. J Clin Oncol. 2005;23:8253–8261
  130. Larson SM, Morris M, Gunther I, et al. Tumor localization of 16beta-18F-fluoro5alpha-dihydrotestosterone versus 18F-FDG in patients with progressive, metastatic prostate cancer. J Nucl Med. 2004;45:366–373
  131. Dehdashti F, Picus J, Michalski JM, et al. Positron tomographic assessment of androgen receptors in prostatic carcinoma. Eur J Nucl Med Mol Imaging. 2005;32:344–350
  132. Rogers BE, Bigott HM, McCarthy DW, et al. MicroPET imaging of a gastrin-releasing peptide receptor-positive tumor in a mouse model of human prostate cancer using a 64Cu-labeled bombesin analogue. Bioconjug Chem. 2003;14:756–763
  133. Chen X, Park R, Hou Y, et al. MicroPET and autoradiographic imaging of GRP receptor expression with 64Cu-dota-[Lys3]bombesin in human prostate adenocarcinoma xenografts. J Nucl Med. 2004;45:1390–1397
  134. Schuhmacher J, Zhang H, Doll J, et al. GRP receptor-targeted PET of a rat pancreas carcinoma xenograft in nude mice with a 68Ga-labeled bombesin(6-14) analog. J Nucl Med. 2005;46:691–699
  135. Zhang X, Cai W, Cao F, et al. 18F-labeled bombesin analogs for targeting GRP receptor-expressing prostate cancer. J Nucl Med. 2006;47:492–501
  136. Schuster DM, Votaw JR, Nieh PT, et al. Initial experience with the radiotracer anti-1-amino-3-18F-fluorocyclobutane-1-carboxylic acid with PET/CT in prostate carcinoma. J Nucl Med. 2007;48:56–63

PII: S0001-2998(09)00042-7

doi: 10.1053/j.semnuclmed.2009.05.003

Seminars in Nuclear Medicine
Volume 39, Issue 6 , Pages 396-407 , November 2009

Article Tools

* Image Usage & Resolution